Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction

Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for fo...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 63; no. 12; pp. 1046 - 1051
Main Authors Swanney, M P, Ruppel, G, Enright, P L, Pedersen, O F, Crapo, R O, Miller, M R, Jensen, R L, Falaschetti, E, Schouten, J P, Hankinson, J L, Stocks, J, Quanjer, P H
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and British Thoracic Society 01.12.2008
BMJ
BMJ Publishing Group LTD
Subjects
Online AccessGet full text
ISSN0040-6376
1468-3296
1468-3296
DOI10.1136/thx.2008.098483

Cover

Loading…
Abstract Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) and its lower limit of normal (LLN) from the literature. FEV1/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17–90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.Results:The LLN for FEV1/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995–1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17–45% of men and 7–26% of women for GOLD; 0–18% of men and 0–16% of women for ATS/ERS; and 0–9% of men and 0–11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Conclusions:Airway obstruction should be defined by FEV1/FVC and FEV1 being below the LLN using appropriate reference equations.
AbstractList The prevalence of airway obstruction varies widely with the definition used. To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations. We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population. The LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations. Airway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations.
Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.Methods:We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) and its lower limit of normal (LLN) from the literature. FEV1/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17–90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.Results:The LLN for FEV1/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995–1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17–45% of men and 7–26% of women for GOLD; 0–18% of men and 0–16% of women for ATS/ERS; and 0–9% of men and 0–11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Conclusions:Airway obstruction should be defined by FEV1/FVC and FEV1 being below the LLN using appropriate reference equations.
The prevalence of airway obstruction varies widely with the definition used.AIMThe prevalence of airway obstruction varies widely with the definition used.To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.OBJECTIVESTo study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations.We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.METHODSWe collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population.The LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.RESULTSThe LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations.Airway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations.CONCLUSIONSAirway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations.
Aim: The prevalence of airway obstruction varies widely with the definition used. Objectives: To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations. Methods: We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV1 /FVC) and its lower limit of normal (LLN) from the literature. FEV1 /FVC from 40â[euro][per thousand]646 adults (including 13â[euro][per thousand]136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV1 /FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population. Results: The LLN for FEV1 /FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations. Conclusions: Airway obstruction should be defined by FEV1 /FVC and FEV1 being below the LLN using appropriate reference equations.
Author Miller, M R
Quanjer, P H
Schouten, J P
Ruppel, G
Swanney, M P
Falaschetti, E
Jensen, R L
Stocks, J
Enright, P L
Pedersen, O F
Crapo, R O
Hankinson, J L
Author_xml – sequence: 1
  givenname: M P
  surname: Swanney
  fullname: Swanney, M P
  email: maureen.swanney@cdhb.govt.nz
  organization: Respiratory Physiology Laboratory, Christchurch Hospital, Canterbury District Health Board, Christchurch, New Zealand
– sequence: 2
  givenname: G
  surname: Ruppel
  fullname: Ruppel, G
  email: maureen.swanney@cdhb.govt.nz
  organization: Pulmonary Function Laboratory, St Louis University Hospital, St Louis, Missouri, USA
– sequence: 3
  givenname: P L
  surname: Enright
  fullname: Enright, P L
  email: maureen.swanney@cdhb.govt.nz
  organization: College of Public Health, The University of Arizona, Tucson, Arizona, USA
– sequence: 4
  givenname: O F
  surname: Pedersen
  fullname: Pedersen, O F
  email: maureen.swanney@cdhb.govt.nz
  organization: Institute of Public Health, Aarhus University, Aarhus, Denmark
– sequence: 5
  givenname: R O
  surname: Crapo
  fullname: Crapo, R O
  email: maureen.swanney@cdhb.govt.nz
  organization: Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA
– sequence: 6
  givenname: M R
  surname: Miller
  fullname: Miller, M R
  email: maureen.swanney@cdhb.govt.nz
  organization: Department of Medicine, University Hospital Birmingham NHS Trust, Birmingham, UK
– sequence: 7
  givenname: R L
  surname: Jensen
  fullname: Jensen, R L
  email: maureen.swanney@cdhb.govt.nz
  organization: Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA
– sequence: 8
  givenname: E
  surname: Falaschetti
  fullname: Falaschetti, E
  email: maureen.swanney@cdhb.govt.nz
  organization: Department of Epidemiology and Public Health, University College London, London, UK
– sequence: 9
  givenname: J P
  surname: Schouten
  fullname: Schouten, J P
  email: maureen.swanney@cdhb.govt.nz
  organization: Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
– sequence: 10
  givenname: J L
  surname: Hankinson
  fullname: Hankinson, J L
  email: maureen.swanney@cdhb.govt.nz
  organization: Valdosta, Georgia, USA
– sequence: 11
  givenname: J
  surname: Stocks
  fullname: Stocks, J
  email: maureen.swanney@cdhb.govt.nz
  organization: Portex Anaesthesia, Intensive Therapy and Respiratory Unit, UCL, Institute of Child Health, London, UK
– sequence: 12
  givenname: P H
  surname: Quanjer
  fullname: Quanjer, P H
  email: maureen.swanney@cdhb.govt.nz
  organization: Department of Pulmonary Diseases, Erasmus Medical Centre, Erasmus University, Rotterdam, The Netherlands
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20849756$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18786983$$D View this record in MEDLINE/PubMed
BookMark eNqFkcFr2zAYxcXoWNNu592GYWyHgRPJsiX5uJmmG5SMwZrDLkKSpVWZbbWSTNv_vnKc5VAYOwn0fu_jfd87AyeDGzQAbxFcIoTJKt48LAsI2RLWrGT4BVigkrAcFzU5AQsIS5gTTMkpOAthBxOIEH0FThGjjNQML8DuOtjhdxZvdNa5e-2zzvY2Zs5kg_O96DLj_F5dX2zRar1tMi-idZnX7ah02Eu9DaoTIVhj1SQOk11Yfy8eMydD9KOafl-Dl0Z0Qb85vOfgen3xs_maX32__NZ8vsplhXHMTQVliZCkiEBcKVMaKGVNWylKLIyua9FiDGulkWaCwFJCyhiklCDSKgwNPgcf57m33t2NOkQ-BdRdJwbtxsDT4ggVGCfw_TNw50Y_pGwcUYZYQQpEE_XuQI2y1y2_9bYX_pH_vWECPhwAEZTojBeDsuHIFZCVNa1I4qqZU96F4LXhysb9vaIXtuMI8qlTnjrlU6d87jT5Vs98xwj_dOSzw4aoH4648H84oZhWfLNt-Kapyl8_4IZ_SfynmZf97r_DnwCD8b7e
CODEN THORA7
CitedBy_id crossref_primary_10_1097_MCP_0000000000001023
crossref_primary_10_1186_s12875_021_01583_w
crossref_primary_10_1002_ppul_24625
crossref_primary_10_1016_j_chest_2021_02_028
crossref_primary_10_1016_j_rmr_2012_09_020
crossref_primary_10_1002_ajim_23693
crossref_primary_10_1080_15412555_2019_1589443
crossref_primary_10_1378_chest_10_0992
crossref_primary_10_1088_1612_2011_10_7_075603
crossref_primary_10_1002_ajim_22366
crossref_primary_10_1186_1465_9921_13_13
crossref_primary_10_4103_lungindia_lungindia_477_24
crossref_primary_10_4103_1687_8426_153586
crossref_primary_10_1038_s41598_020_60478_5
crossref_primary_10_1080_07315724_2013_767652
crossref_primary_10_2174_1573398X18666220903121800
crossref_primary_10_3390_antiox10060883
crossref_primary_10_1007_s11897_014_0212_x
crossref_primary_10_1080_10408444_2017_1315363
crossref_primary_10_1093_annweh_wxaa014
crossref_primary_10_1016_j_chemosphere_2018_12_079
crossref_primary_10_1016_j_prrv_2021_05_006
crossref_primary_10_1183_09031936_00193809
crossref_primary_10_1186_s12859_020_03785_y
crossref_primary_10_1038_s41409_024_02265_8
crossref_primary_10_1109_TBME_2023_3250650
crossref_primary_10_1097_ACI_0000000000000146
crossref_primary_10_1016_j_chest_2024_08_048
crossref_primary_10_1021_acs_est_2c04972
crossref_primary_10_1186_s12890_017_0537_9
crossref_primary_10_35366_NTS191A
crossref_primary_10_1002_ajim_22495
crossref_primary_10_1152_japplphysiol_00439_2019
crossref_primary_10_1186_s13104_015_1731_6
crossref_primary_10_1378_chest_10_0189
crossref_primary_10_3760_cma_j_issn_0366_6999_20121090
crossref_primary_10_1183_13993003_01499_2021
crossref_primary_10_1136_bmjresp_2023_001793
crossref_primary_10_1183_09031936_00135110
crossref_primary_10_1186_1745_6673_9_21
crossref_primary_10_1016_j_rmed_2013_04_008
crossref_primary_10_1080_15412555_2018_1531388
crossref_primary_10_3109_02770903_2013_860164
crossref_primary_10_1021_acsnano_1c09792
crossref_primary_10_3390_diagnostics13203261
crossref_primary_10_1093_occmed_kqaa023
crossref_primary_10_2147_COPD_S319220
crossref_primary_10_1016_j_arbres_2023_10_002
crossref_primary_10_26416_Pedi_62_2_2021_4890
crossref_primary_10_1210_clinem_dgaa296
crossref_primary_10_1183_20734735_0346_2018
crossref_primary_10_1007_s10772_019_09608_7
crossref_primary_10_1080_17476348_2017_1334553
crossref_primary_10_4046_trd_2016_79_3_121
crossref_primary_10_1183_23120541_00718_2022
crossref_primary_10_1002_ejhf_946
crossref_primary_10_1016_j_rmed_2023_107523
crossref_primary_10_1111_j_1440_1843_2010_01830_x
crossref_primary_10_1097_MD_0000000000027124
crossref_primary_10_1186_s12889_024_17686_9
crossref_primary_10_3310_hta19360
crossref_primary_10_1002_ajim_23474
crossref_primary_10_1007_s00420_022_01922_z
crossref_primary_10_33667_2078_5631_2022_20_16_22
crossref_primary_10_2217_cpr_14_28
crossref_primary_10_1183_09031936_00108409
crossref_primary_10_1513_AnnalsATS_201707_571OC
crossref_primary_10_1128_spectrum_02139_21
crossref_primary_10_1136_bjsports_2022_106136
crossref_primary_10_1183_20734735_020117
crossref_primary_10_1080_15412555_2019_1566894
crossref_primary_10_1159_000508163
crossref_primary_10_1183_13993003_00918_2015
crossref_primary_10_1080_20018525_2024_2387405
crossref_primary_10_1093_eurheartj_eht192
crossref_primary_10_1002_clc_22802
crossref_primary_10_1016_j_cali_2017_05_001
crossref_primary_10_1177_1176934319888904
crossref_primary_10_1177_0272989X18824098
crossref_primary_10_1002_ajim_23244
crossref_primary_10_1183_09031936_00049909
crossref_primary_10_1177_1479164117746022
crossref_primary_10_3810_pgm_2010_09_2212
crossref_primary_10_4187_respcare_07069
crossref_primary_10_1016_j_envint_2016_05_006
crossref_primary_10_1136_bmjopen_2018_025132
crossref_primary_10_1371_journal_pone_0123626
crossref_primary_10_1016_S2213_2600_13_70086_9
crossref_primary_10_1016_j_rmr_2010_10_025
crossref_primary_10_1164_rccm_201608_1545OC
crossref_primary_10_1016_j_rmr_2014_01_003
crossref_primary_10_1186_s40798_015_0021_0
crossref_primary_10_3945_ajcn_112_040774
crossref_primary_10_1016_j_ebiom_2024_105453
crossref_primary_10_1038_s41598_021_92911_8
crossref_primary_10_1186_s12890_023_02403_w
crossref_primary_10_1155_2016_5478394
crossref_primary_10_1378_chest_10_1721
crossref_primary_10_2147_COPD_S232863
crossref_primary_10_1016_j_rmed_2017_12_004
crossref_primary_10_1080_02770903_2018_1531997
crossref_primary_10_1016_j_rmed_2011_01_008
crossref_primary_10_1080_03014460_2019_1572223
crossref_primary_10_2147_COPD_S377140
crossref_primary_10_3390_genes14040798
crossref_primary_10_4046_trd_2011_70_4_293
crossref_primary_10_1183_23120541_00110_2017
crossref_primary_10_2169_internalmedicine_50_4412
crossref_primary_10_3109_15412555_2011_626817
crossref_primary_10_1080_02770903_2022_2144349
crossref_primary_10_3402_ecrj_v2_27768
crossref_primary_10_1186_1471_2466_14_206
crossref_primary_10_1080_15412555_2020_1758050
crossref_primary_10_3109_15412555_2015_1048851
crossref_primary_10_1186_s12890_019_0976_6
crossref_primary_10_1080_0361073X_2018_1521374
crossref_primary_10_1183_09031936_00172908
crossref_primary_10_1378_chest_10_1117
crossref_primary_10_1183_20734735_0227_2023
crossref_primary_10_1186_1471_2466_10_35
crossref_primary_10_1164_rccm_200810_1540OC
crossref_primary_10_1111_resp_12388
crossref_primary_10_1513_AnnalsATS_201710_830LE
crossref_primary_10_1183_23120541_00084_2015
crossref_primary_10_1016_S0140_6736_15_60647_X
crossref_primary_10_1183_09031936_00176811
crossref_primary_10_1016_j_envres_2020_109847
crossref_primary_10_1183_13993003_01575_2015
crossref_primary_10_4187_respcare_04965
crossref_primary_10_1183_09031936_00164608
crossref_primary_10_2196_resprot_7422
crossref_primary_10_15324_kjcls_2020_52_2_119
crossref_primary_10_1055_s_0040_1705662
crossref_primary_10_1183_13993003_02339_2014
crossref_primary_10_6000_1929_5634_2013_02_01_2
crossref_primary_10_1016_j_disamonth_2016_03_002
crossref_primary_10_1111_resp_12179
crossref_primary_10_1097_JOM_0b013e3181fc5e50
crossref_primary_10_1038_nrdp_2015_76
crossref_primary_10_2147_COPD_S338359
crossref_primary_10_3390_diagnostics11071189
crossref_primary_10_1164_rccm_201604_0871OC
crossref_primary_10_1007_s12445_015_0131_4
crossref_primary_10_1183_09031936_00178109
crossref_primary_10_1111_resp_13262
crossref_primary_10_1016_S2213_2600_16_30149_7
crossref_primary_10_1093_ije_dyw318
crossref_primary_10_1159_000366064
crossref_primary_10_1186_2049_6958_5_6_437
crossref_primary_10_4187_respcare_07536
crossref_primary_10_1183_09031936_00134214
crossref_primary_10_1136_bmjopen_2018_023673
crossref_primary_10_3109_15412555_2013_773303
crossref_primary_10_1164_rccm_201511_2239ED
crossref_primary_10_1016_j_rmed_2014_07_018
crossref_primary_10_1136_oemed_2013_101654
crossref_primary_10_1164_rccm_201701_0205OC
crossref_primary_10_1111_resp_12855
crossref_primary_10_1371_journal_pone_0296470
crossref_primary_10_18857_jkpt_2018_30_3_96
crossref_primary_10_3109_15412555_2014_948998
crossref_primary_10_1007_s10055_023_00892_y
crossref_primary_10_1038_srep28029
crossref_primary_10_1183_13993003_01585_2021
crossref_primary_10_1080_15412555_2019_1698530
crossref_primary_10_1002_acr_22686
crossref_primary_10_1136_oemed_2015_103406
crossref_primary_10_1183_13993003_00403_2018
crossref_primary_10_37349_eaa_2024_00031
crossref_primary_10_1183_09031936_00110010
crossref_primary_10_1080_10773525_2016_1176328
crossref_primary_10_1002_ajim_23445
crossref_primary_10_1016_j_rmed_2018_09_014
crossref_primary_10_1016_j_rmr_2013_11_007
crossref_primary_10_1038_s41556_021_00762_2
crossref_primary_10_1186_s12890_021_01590_8
crossref_primary_10_1111_resp_12040
crossref_primary_10_1080_15412555_2019_1641794
crossref_primary_10_1016_j_rmr_2010_09_007
crossref_primary_10_1139_h11_075
crossref_primary_10_1371_journal_pone_0205273
crossref_primary_10_1080_15412555_2017_1339681
crossref_primary_10_1097_HCR_0000000000000871
crossref_primary_10_1164_rccm_202311_2145OC
crossref_primary_10_4103_1687_8426_203803
crossref_primary_10_1016_j_rmed_2011_06_012
crossref_primary_10_1158_1055_9965_EPI_21_1365
crossref_primary_10_1097_ACI_0b013e3283300baf
crossref_primary_10_1371_journal_pone_0149760
crossref_primary_10_1164_rccm_201611_2282LE
crossref_primary_10_1183_09031936_00190010
crossref_primary_10_1007_s10405_011_0521_7
crossref_primary_10_3109_15412555_2013_781996
crossref_primary_10_3390_s16081305
crossref_primary_10_9738_INTSURG_D_13_00060_1
crossref_primary_10_1183_13993003_00186_2019
crossref_primary_10_1136_thoraxjnl_2016_209665
crossref_primary_10_3109_02770903_2014_895012
crossref_primary_10_1093_hmg_ddv378
crossref_primary_10_2147_COPD_S295321
crossref_primary_10_1080_03009742_2023_2194105
crossref_primary_10_1136_thorax_2024_221813
crossref_primary_10_3238_arztebl_2014_0834
crossref_primary_10_1093_aje_kwz185
crossref_primary_10_2147_COPD_S361839
crossref_primary_10_1016_j_chest_2021_01_067
crossref_primary_10_1016_j_rmed_2020_106202
crossref_primary_10_1186_1465_9921_14_61
crossref_primary_10_1186_s12890_020_1091_4
crossref_primary_10_1016_j_resmer_2022_100891
crossref_primary_10_1016_j_pccm_2023_03_004
crossref_primary_10_1183_09031936_00126011
crossref_primary_10_1183_09059180_00003609
crossref_primary_10_2188_jea_JE20170220
crossref_primary_10_3390_toxics8030053
crossref_primary_10_3346_jkms_2024_39_e20
crossref_primary_10_1183_13993003_02129_2019
crossref_primary_10_1186_1471_2466_12_12
crossref_primary_10_1016_j_resp_2015_08_002
crossref_primary_10_1016_j_rmed_2010_12_017
crossref_primary_10_1164_rccm_201202_0366OC
crossref_primary_10_2147_COPD_S382761
crossref_primary_10_1016_j_rmed_2018_04_011
crossref_primary_10_1056_NEJMc1914600
crossref_primary_10_1002_iid3_307
crossref_primary_10_4187_respcare_04650
crossref_primary_10_1183_09031936_00042215
crossref_primary_10_3233_JPD_212565
crossref_primary_10_1016_j_chest_2018_01_038
crossref_primary_10_1002_flm2_10
crossref_primary_10_1136_bmjresp_2020_000575
crossref_primary_10_2169_internalmedicine_49_3364
crossref_primary_10_1016_j_chest_2019_02_001
crossref_primary_10_1186_s40246_016_0076_0
crossref_primary_10_1016_j_rmr_2023_06_004
crossref_primary_10_1513_AnnalsATS_202103_284ST
crossref_primary_10_17816_RFD2012429_34
crossref_primary_10_1080_15412555_2019_1653271
crossref_primary_10_4187_respcare_01816
crossref_primary_10_1016_j_rmed_2016_12_008
crossref_primary_10_1513_AnnalsATS_201703_194OC
crossref_primary_10_1016_j_cardfail_2012_05_008
crossref_primary_10_1017_S0959259809990293
crossref_primary_10_1111_j_1440_1843_2010_01850_x
crossref_primary_10_1111_resp_12771
crossref_primary_10_2147_JAA_S403645
crossref_primary_10_4046_trd_2017_80_2_105
crossref_primary_10_1164_rccm_201406_1166OC
crossref_primary_10_1016_j_arbres_2022_11_014
crossref_primary_10_1016_j_mcna_2012_04_011
crossref_primary_10_1038_npjpcrm_2014_33
crossref_primary_10_1136_bmjopen_2011_000153
crossref_primary_10_1183_09031936_00107709
crossref_primary_10_1080_15412555_2024_2402706
crossref_primary_10_4187_respcare_05710
crossref_primary_10_1183_13993003_00635_2015
crossref_primary_10_1016_j_ejim_2013_01_008
crossref_primary_10_1007_s00059_019_4814_7
crossref_primary_10_1016_S0140_6736_14_60446_3
crossref_primary_10_1016_S2213_2600_17_30293_X
crossref_primary_10_1136_thoraxjnl_2012_202810
crossref_primary_10_1016_j_alit_2019_04_009
crossref_primary_10_13066_kspm_2016_11_2_123
crossref_primary_10_4046_trd_2012_72_3_310
crossref_primary_10_1037_cpp0000256
crossref_primary_10_36416_1806_3756_e20210124
crossref_primary_10_1378_chest_09_2681
crossref_primary_10_1016_j_resinv_2014_08_002
crossref_primary_10_1186_s12882_017_0565_y
crossref_primary_10_1186_1472_6963_11_37
crossref_primary_10_1136_thoraxjnl_2013_204460
crossref_primary_10_1038_s41598_020_73117_w
crossref_primary_10_1111_jth_13525
crossref_primary_10_1183_13993003_00477_2019
crossref_primary_10_2471_BLT_18_216523
crossref_primary_10_3109_15412555_2014_922173
crossref_primary_10_1080_24745332_2022_2048980
crossref_primary_10_3389_fped_2019_00054
crossref_primary_10_18231_j_ijcap_2023_052
crossref_primary_10_1136_bmjopen_2018_028150
crossref_primary_10_1378_chest_10_2052
crossref_primary_10_1016_j_mtchem_2024_102024
crossref_primary_10_1111_resp_12793
crossref_primary_10_1136_bmjopen_2019_035885
crossref_primary_10_1183_09031936_00123613
crossref_primary_10_1016_j_jacc_2018_06_045
crossref_primary_10_1136_bmjresp_2020_000664
crossref_primary_10_4104_pcrj_2014_00006
crossref_primary_10_4187_respcare_04323
crossref_primary_10_3390_diagnostics11050785
crossref_primary_10_1016_j_rmed_2017_01_004
crossref_primary_10_1113_jphysiol_2014_282863
crossref_primary_10_1080_02770903_2018_1477956
crossref_primary_10_1155_2017_6287642
crossref_primary_10_1111_j_1440_1843_2009_01553_x
crossref_primary_10_3109_15412555_2011_650802
crossref_primary_10_1016_j_hrtlng_2013_07_002
crossref_primary_10_4104_pcrj_2013_00048
crossref_primary_10_1111_resp_12540
crossref_primary_10_1183_09031936_00195512
crossref_primary_10_1024_0301_1526_a001168
crossref_primary_10_1093_icvts_ivz049
crossref_primary_10_1016_S2213_2600_14_70040_2
crossref_primary_10_1002_ajim_20792
crossref_primary_10_1016_j_cegh_2013_04_002
crossref_primary_10_1183_13993003_02325_2014
crossref_primary_10_2147_COPD_S280157
crossref_primary_10_1164_rccm_201201_0051OC
crossref_primary_10_1080_17476348_2016_1190274
crossref_primary_10_1097_JOM_0b013e318229aaff
crossref_primary_10_1186_s12890_019_0946_z
crossref_primary_10_1016_j_ejim_2012_12_009
crossref_primary_10_1111_j_1440_1843_2011_01987_x
crossref_primary_10_1183_09031936_00158212
crossref_primary_10_1097_JOM_0b013e31828b22cc
crossref_primary_10_1183_09031936_00143209
crossref_primary_10_1056_NEJMoa1513737
crossref_primary_10_5320_wjr_v3_i3_57
crossref_primary_10_1186_s12940_018_0373_2
crossref_primary_10_1016_j_chest_2016_06_047
crossref_primary_10_1016_j_ccm_2020_06_004
crossref_primary_10_1183_09031936_00103309
crossref_primary_10_1378_chest_11_2718
crossref_primary_10_4103_lungindia_lungindia_300_18
crossref_primary_10_4236_ojanes_2015_53008
crossref_primary_10_1164_rccm_201306_1031LE
crossref_primary_10_1331_JAPhA_2012_11100
crossref_primary_10_2147_JAA_S366453
crossref_primary_10_1016_j_jaip_2016_02_014
crossref_primary_10_23950_jcmk_10919
crossref_primary_10_3238_PersPneumo_2019_02_15_003
crossref_primary_10_1016_j_resp_2023_104094
crossref_primary_10_3402_ecrj_v3_30658
crossref_primary_10_1136_bmjopen_2014_005685
crossref_primary_10_1183_09031936_00074614
crossref_primary_10_1111_imj_14047
crossref_primary_10_1097_ADM_0000000000000103
crossref_primary_10_1186_1465_9921_11_180
crossref_primary_10_1016_S0027_9684_15_30623_4
crossref_primary_10_1088_1752_7155_7_1_017108
crossref_primary_10_1016_j_chest_2020_04_064
crossref_primary_10_1016_j_heliyon_2023_e20744
crossref_primary_10_1590_s1806_37562017000000276
crossref_primary_10_1183_09031936_00231414
crossref_primary_10_1183_09031936_00007711
crossref_primary_10_4187_respcare_01160
crossref_primary_10_1136_thoraxjnl_2020_216523
crossref_primary_10_1183_09059180_00005509
crossref_primary_10_1016_S1877_1203_10_70033_1
crossref_primary_10_1136_bmjresp_2023_002142
crossref_primary_10_1183_13993003_01878_2015
crossref_primary_10_1136_bmjopen_2013_002561
crossref_primary_10_1016_j_rmed_2019_08_004
crossref_primary_10_1186_s12931_018_0911_z
crossref_primary_10_3399_bjgp18X700385
crossref_primary_10_2165_11535220_000000000_00000
crossref_primary_10_1186_s12889_015_2161_z
crossref_primary_10_1164_rccm_201709_1861OC
crossref_primary_10_1021_acsami_2c21680
crossref_primary_10_4103_0970_2113_116248
crossref_primary_10_1183_23120541_00034_2020
crossref_primary_10_1183_09031936_00019009
ContentType Journal Article
Copyright 2008 BMJ Publishing Group and British Thoracic Society
2008 INIST-CNRS
Copyright: 2008 2008 BMJ Publishing Group and British Thoracic Society
Copyright_xml – notice: 2008 BMJ Publishing Group and British Thoracic Society
– notice: 2008 INIST-CNRS
– notice: Copyright: 2008 2008 BMJ Publishing Group and British Thoracic Society
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
BTHHO
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1136/thx.2008.098483
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
BMJ Journals
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
BMJ Journals
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
ProQuest One Academic Middle East (New)

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-3296
EndPage 1051
ExternalDocumentID 4027206741
18786983
20849756
10_1136_thx_2008_098483
ark_67375_NVC_NC54ZQ0N_B
thoraxjnl
Genre Multicenter Study
Journal Article
GeographicLocations United Kingdom--UK
England
United States--US
GeographicLocations_xml – name: England
– name: United Kingdom--UK
– name: United States--US
GroupedDBID ---
.55
.GJ
.VT
08G
0R~
123
18M
29Q
2WC
354
39C
3O-
4.4
40O
53G
5RE
5VS
6PF
7X7
7~S
88E
8F7
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAYEP
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADZCM
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
E3Z
EBS
EJD
F5P
FEDTE
FYUFA
GX1
H13
HAJ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IH2
IHR
IOF
ITC
J5H
KQ8
L7B
M1P
N4W
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W8F
WH7
X7M
YFH
YOC
YQY
ZCG
ZGI
BSCLL
AAYXX
ACQHZ
ADGHP
AERUA
CITATION
PHGZM
IQODW
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-b533t-f50b411b716035cf4f0bb97dba43afe99ad3309ce1e8a604b0788077616dc30f3
IEDL.DBID 7X7
ISSN 0040-6376
1468-3296
IngestDate Tue Aug 05 09:42:54 EDT 2025
Sun Aug 17 05:41:00 EDT 2025
Thu Apr 03 06:56:51 EDT 2025
Mon Jul 21 09:15:54 EDT 2025
Thu Apr 24 23:06:21 EDT 2025
Tue Jul 01 02:30:50 EDT 2025
Tue Mar 18 09:38:07 EDT 2025
Thu Apr 24 23:02:55 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Respiratory disease
Anesthesia
Airways obstruction
Ratio
Circulatory system
Limit
Cardiology
Normal
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b533t-f50b411b716035cf4f0bb97dba43afe99ad3309ce1e8a604b0788077616dc30f3
Notes istex:E109320FFB206D680C634135AD78AAB38BDF7CB3
PMID:18786983
Supplementary reference values data are published online only at http://thorax.bmj.com/content/vol63/issue12
local:thoraxjnl;63/12/1046
ark:/67375/NVC-NC54ZQ0N-B
ArticleID:tx98483
href:thoraxjnl-63-1046.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://thorax.bmj.com/content/thoraxjnl/63/12/1046.full.pdf
PMID 18786983
PQID 1781826217
PQPubID 2041050
PageCount 6
ParticipantIDs proquest_miscellaneous_69811233
proquest_journals_1781826217
pubmed_primary_18786983
pascalfrancis_primary_20849756
crossref_citationtrail_10_1136_thx_2008_098483
crossref_primary_10_1136_thx_2008_098483
istex_primary_ark_67375_NVC_NC54ZQ0N_B
bmj_primary_10_1136_thx_2008_098483
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2008-12-01
PublicationDateYYYYMMDD 2008-12-01
PublicationDate_xml – month: 12
  year: 2008
  text: 2008-12-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Thorax
PublicationTitleAlternate Thorax
PublicationYear 2008
Publisher BMJ Publishing Group Ltd and British Thoracic Society
BMJ
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd and British Thoracic Society
– name: BMJ
– name: BMJ Publishing Group LTD
References Hansen, Sun, Wasserman 2007; 131
Cerveri, Corsico, Accordini 2008; 63
Roberts, Farber, Knox 2006; 130
Price, Tinkelman, Nordyke 2006; 129
Medbø, Melbye 2007; 101
Quanjer 1983; 19
2004; 23
Culver 2006; 51
Jones, Agusti 2006; 27
Quanjer, Tammeling, Cotes 1993; 6
Enright 2007; 62
Falaschetti, Laiho, Primatesta 2004; 23
Halbert, Isonaka, George 2003; 123
Perez-Padilla, Hallil, Vazquez-Garcia 2007; 4
Gräsbeck 2004; 42
Hnizdo, Glindmeyer, Petsonk 2006; 3
Celli, Halbert, Isonaka 2003; 22
Van Pelt, Borsboom, Rijcken 1994; 149
Pellegrino, Viegi, Brusasco 2005; 26
Lin, Watkins, Johnson 2008; 148
1991; 144
1987; 136
Viegi, Pedreschi, Pistelli 2000; 117
Shirtcliffe, Weatherall, Marsh 2007; 30
1997; 52
Fletcher, Peto 1977; 1
Siafakas, Vermeire, Pride 1995; 8
Hardie, Buist, Vollmer 2002; 20
Heath 2005; 330
Hankinson, Odencrantz, Fedan 1995; 152
Ferguson, Enright, Buist 2000; 117
Van der Lende, Orie 1972; 53
Lebowitz, Holberg 1990; 141
19020267 - Thorax. 2008 Dec;63(12):1031-2
References_xml – volume: 144
  start-page: 1202
  year: 1991
  article-title: Lung function testing: Selection of reference values and interpretative strategies.
  publication-title: Am Rev Respir Dis
– volume: 23
  start-page: 932
  year: 2004
  article-title: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
  publication-title: Eur Respir J
– article-title: Clinical Guideline 12. Chronic obstructive pulmonary disease February 2004.
– volume: 63
  start-page: 1040
  year: 2008
  article-title: Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes.
  publication-title: Thorax
– volume: 8
  start-page: 1398
  year: 1995
  article-title: Optimal assessment and management of chronic obstructive pulmonary disease. A consensus statement of the European Respiratory Society (ERS).
  publication-title: Eur Respir J
– volume: 42
  start-page: 692
  year: 2004
  article-title: The evolution of the reference value concept.
  publication-title: Clin Chem Lab Med
– volume: 117
  start-page: 339S
  year: 2000
  article-title: Prevalence of airways obstruction in a general population. European Respiratory Society vs. American Thoracic Society definition.
  publication-title: Chest
– volume: 149
  start-page: 1218
  year: 1994
  article-title: Discrepancies between longitudinal and cross-sectional change in ventilatory function in 12 years of follow-up.
  publication-title: Am J Respir Crit Care Med
– volume: 53
  start-page: 218
  year: 1972
  article-title: The MRC/ECCS questionnaire on respiratory symptoms: use in epidemiology.
  publication-title: Scand J Respir Dis
– volume: 1
  start-page: 1645
  year: 1977
  article-title: The natural history of chronic airflow obstruction.
  publication-title: BMJ
– volume: 152
  start-page: 179
  year: 1995
  article-title: Spirometric reference values from a sample of the general US population.
  publication-title: Am J Respir Crit Care Med
– volume: 62
  start-page: 1107
  year: 2007
  article-title: GOLD stage I is not a COPD risk factor.
  publication-title: Thorax
– volume: 20
  start-page: 1117
  year: 2002
  article-title: Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.
  publication-title: Eur Respir J
– volume: 131
  start-page: 349
  year: 2007
  article-title: Spirometric criteria for airway obstruction. Use percentage of FEV1/FVC ratio below the fifth percentile, not<70%.
  publication-title: Chest
– volume: 141
  start-page: 1491
  year: 1990
  article-title: Comparisons of spirometric reference values and the proportions of abnormal subjects among male smokers and those symptomatic in a community population.
  publication-title: Am Rev Respir Dis
– volume: 27
  start-page: 822
  year: 2006
  article-title: Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
  publication-title: Eur Respir J
– article-title: Download software and consult the associated documentation for full details (accessed 3 October 2008).
– volume: 51
  start-page: 719
  year: 2006
  article-title: Interpretation of spirometry: we can do better than the GOLD standard.
  publication-title: Chest
– volume: 123
  start-page: 1684
  year: 2003
  article-title: Interpreting COPD prevalence estimates: What is the true burden of disease?
  publication-title: Chest
– volume: 129
  start-page: 1531
  year: 2006
  article-title: Scoring system and clinical application of COPD diagnostic questionnaires.
  publication-title: Chest
– volume: 6
  start-page: 5
  year: 1993
  article-title: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.
  publication-title: Eur Respir J
– volume: 23
  start-page: 456
  year: 2004
  article-title: Prediction equations for normal and low lung function from the Health Survey for England.
  publication-title: Eur Respir J
– volume: 26
  start-page: 948
  year: 2005
  article-title: Interpretative strategies for lung function tests. Series “ATS/ERS Task Force: Standardisation of lung function testing”.
  publication-title: Eur Respir J
– volume: 3
  start-page: 1
  year: 2006
  article-title: Case definitions for chronic obstructive pulmonary disease.
  publication-title: COPD
– volume: 130
  start-page: 200
  year: 2006
  article-title: FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age.
  publication-title: Chest
– volume: 30
  start-page: 232
  year: 2007
  article-title: COPD prevalence in a random population survey: a matter of definition.
  publication-title: Eur Respir J
– volume: 4
  start-page: 113
  year: 2007
  article-title: Impact of bronchodilator use on the prevalence of COPD in population-based samples.
  publication-title: COPD
– volume: 136
  start-page: 225
  year: 1987
  article-title: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.
  publication-title: Am Rev Respir Dis
– volume: 52
  start-page: 1
  year: 1997
  publication-title: Thorax
– volume: 19
  start-page: 1
  year: 1983
  article-title: Standardized lung function testing. Report Working Party ‘Standardization of lung function tests’ of ECCS.
  publication-title: Bull Europ Physiopath Respir
– volume: 117
  start-page: 1146
  year: 2000
  article-title: Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program.
  publication-title: Chest
– volume: 101
  start-page: 1097
  year: 2007
  article-title: Lung function testing in the elderly—Can we still use the FEV1/FVC <70% as a criterion for COPD?
  publication-title: Respir Med
– volume: 22
  start-page: 268
  year: 2003
  article-title: Population impact of different definitions of airway obstruction.
  publication-title: Eur Respir J
– volume: 330
  start-page: 1461
  year: 2005
  article-title: Thresholds for normal blood pressure and serum cholesterol.
  publication-title: BMJ
– volume: 148
  start-page: 535
  year: 2008
  article-title: Screening for chronic obstructive pulmonary disease using spirometry: Summary of the evidence for the U.S. Preventive Services Task Force.
  publication-title: Ann Intern Med
– reference: 19020267 - Thorax. 2008 Dec;63(12):1031-2
SSID ssj0008117
Score 2.469576
Snippet Aim:The prevalence of airway obstruction varies widely with the definition used.Objectives:To study differences in the prevalence of airway obstruction when...
Aim: The prevalence of airway obstruction varies widely with the definition used. Objectives: To study differences in the prevalence of airway obstruction when...
The prevalence of airway obstruction varies widely with the definition used. To study differences in the prevalence of airway obstruction when applying four...
The prevalence of airway obstruction varies widely with the definition used.AIMThe prevalence of airway obstruction varies widely with the definition used.To...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1046
SubjectTerms Adolescent
Adult
Age
Aged
Aged, 80 and over
Airway management
Asymptomatic
Biological and medical sciences
Cardiology. Vascular system
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease, asthma
Diagnostic Errors
Female
Forced Expiratory Volume - physiology
Health care
Health education
Health surveys
Humans
Lung diseases
Male
Medical sciences
Middle Aged
Pneumology
Practice Guidelines as Topic - standards
Predictive Value of Tests
Pulmonary Disease, Chronic Obstructive - diagnosis
Reference Values
Spirometry
Vital Capacity - physiology
Womens health
Young Adult
Title Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction
URI https://api.istex.fr/ark:/67375/NVC-NC54ZQ0N-B/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/18786983
https://www.proquest.com/docview/1781826217
https://www.proquest.com/docview/69811233
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZglRAv0_gdNoolEOIlNK6dxH5CrGqZkBYBYlXFi2UnjtjWJaMpYvz33Llupj0MHqPLWdbd2f5sf74j5LVwgNrT1MZGqToWJWOxqioVcy6EEmNhVIU3usdFdnQiPi3SRThw6wKtcjsn-om6aks8Ix-xXCIUBgT9_vJnjFWj8HY1lNC4SwaYugw3X_mi33Al-Ihyy5rLYCSF1D6MZ6P1j6tApFRS-JyB9uLsxto0QDNfIVfSdGCuelPn4nYg6hek2R7ZDUiSfti4_gG545qH5N5xuCt_RM48G4ACwKNLLIVGl_iWibY1bRCnLinAVS-dTedsNJtPqA8GusJkrq7zIgiCEuE18om8C1HdnK5-mz-0tX3u2cfkZDb9NjmKQ2WF2AK8W8d1mljBmM2xyHRa1qJOrFV5ZY3gpnZKmYrzRJWOOWmyRFgAEhIT_7CsKnlS8ydkp2kb94xQA_jHlJU0nBmhxk65hNvMSgNASeZWRuQVWFZfbnJnaL_n4JkG-4cKmN7-EXm3tbwuQ3JyrJGxvF3hba_w37bfeFf2_5nVOdLZ8lQX84kuJqn4_iUp9GFEhjd83SuMEylUnmYROdg6X4eh3unrwIzIy16M_kH6WuPaX53OFITimENXnm5C5rrPMpcg5c__3fQ-ue-JKp5Hc0B2wL_uBaChtR36kB-SweG0-PwVvj4u2F8jYgZ_
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKwEXxJtAaS3xEJewSewk9gEhWLra0m4kpHa16sXYiSMoy6ZsFrX9U_xGZpxH1UPh1LMzljUz9nwTf54h5CW3gNrj2PhaytLneRj6siikzxjnkkdcywJvdCdZMj7kn2fxbI386d7CIK2yOxPdQV1UOf4jH4SpQCgMCPr9yS8fu0bh7WrXQqNxiz17fgopW_1u9xPY91UUjXYOhmO_7SrgG4A2K7-MA8PD0KTYYDnOS14Gxsi0MJozXVopdQE5vsxtaIVOAm4giAosehMmRc6CksG8N8gGBN4AKYTprE_wAny02bH0Eti5bSmhkCWD1bezlrgpBXc1Cs3P40uxcAPNeobcTF2Decqmr8bVwNcFwNFdcqdFrvRD42r3yJpd3Cc3J-3d_ANy7NgHFAAlnWPrNTrHt1O0KukCcfGcAjx2o6OdaTgYTYfUOR9dYvFYW7shcLoc4Tzyl5zLoLj-vjzV57Qyfa3bh-TwWnT-iKwvqoV9QqgGvKXzQmgWai4jK23ATGKEBmAmUiM88gI0q06aWh3K5TgsUaD_tuOm079H3naaV3lbDB17csyvFnjTC_x37tfOlP13evkD6XNprLLpUGXDmB99CTL10SNbl2zdC0SB4DKNE49sdsZX7dFSq4uN4JHtfhjtg3S5ha1-1yqR4IoRg6U8blzmYs0iFTDKnv576m1ya3ww2Vf7u9neM3LbkWQch2eTrIOt7XNAYiuz5dyfkq_Xvd_-AutzQHM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKK1VcEG8CpbXEQ1zCJrGT2AeEYNuopTQCia5WvRg7cQRlScruorZ_jV_HjPOoeiicep6MZc3D_hx_niHkObeA2uPY-FrKyudFGPqyLKXPGOeSR1zLEm90D_Jk95B_mMbTFfKnfwuDtMp-TXQLddkU-I98FKYCoTAg6FHV0SI-bWdvT3752EEKb1r7dhptiOzb81M4vi3e7G2Dr19EUbbzZbzrdx0GfAMwZ-lXcWB4GJoUmy3HRcWrwBiZlkZzpisrpS7hvC8LG1qhk4Ab2FAFFsAJk7JgQcVg3BtkLWWwbUIupdPhsBfgA86esZdAFndlhUKWjJbfzjoSpxTc1Ss0P48v7Ytr6OIz5GnqBbiqantsXA2C3WaY3Sa3OhRL37Vhd4es2PouWT_o7unvkWPHRKAALukM27DRGb6jok1Fa8TIMwpQ2UmznUk4yiZj6gKRzrGQrF04EQRggdAeuUwufFBdf5-f6nPamKHu7X1yeC02f0BW66a2jwjVgL10UQrNQs1lZKUNmEmM0ADSRGqER56BZdVJW7dDufMOSxTYv-u-6ezvkde95VXRFUbH_hyzqxVeDQr_Hfulc-XwnZ7_QCpdGqt8Mlb5OOZHn4NcvffI5iVfDwpRILhM48QjG73zVbfMLNRFUnhkaxCjf5A6V9vm90IlEkIxYjCVh23IXMxZpAKk7PG_h94i65Bp6uNevv-E3HR8GUfn2SCr4Gr7FEDZ0my66Kfk63Wn218KB0Sp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+the+lower+limit+of+normal+for+the+FEV1%2FFVC+ratio+reduces+the+misclassification+of+airway+obstruction&rft.jtitle=Thorax&rft.au=Swanney%2C+M+P&rft.au=Ruppel%2C+G&rft.au=Enright%2C+P+L&rft.au=Pedersen%2C+O+F&rft.date=2008-12-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=0040-6376&rft.eissn=1468-3296&rft.volume=63&rft.issue=12&rft.spage=1046&rft_id=info:doi/10.1136%2Fthx.2008.098483&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4027206741
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-6376&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-6376&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-6376&client=summon